Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, Ximing Tang, Gabriela Raso, Robert J Cardnell, Natalie Vokes, George Blumenschein, Yasir Elamin, Frank Fosella, Anne Tsao, Ferdinandos Skoulidis, Celyne Bueno Hume, Koji Sasak, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Hai Tran, Jianjun Zhang, Don Gibbons, Ara Vaporciyan, Jing Wang, Keunchil Park, John V Heymach, Lauren A Byers, Carl M Gay, Xiuning Le
INTRODUCTION: NSCLC transformation to SCLC has been best characterized with EGFR -mutant NSCLC, with emerging case reports seen in ALK , RET , and KRAS -altered NSCLC. Previous reports revealed transformed SCLC from EGFR -mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses revealed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been reported on the detailed clinicogenomic characteristics and potential therapeutic targets for this patient population...
February 2024: JTO clinical and research reports